These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 121157)

  • 1. Studies on tetrahydrofuranyl-5-fluorouracils. 2. NMR studies of 1-(tetrahydro-2-furanyl)-, 3-(tetrahydro-2-furanyl)-, and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracils.
    Yasumoto M; Ueda S; Yamashita J; Hashimoto S
    Nucleic Acids Symp Ser; 1979; (6):s85-8. PubMed ID: 121157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolism of 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil in mice.
    Fujimoto S; Ishigami H; Minami T; Miyazaki M; Itoh K; Kimura K
    J Natl Cancer Inst; 1979 Aug; 63(2):465-8. PubMed ID: 379401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human urinary metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftoraful).
    Benvenuto JA; Liehr JG; Winkler T; Farquhar D; Caprioli RM; Loo TL
    Cancer Res; 1979 Aug; 39(8):3199-201. PubMed ID: 378368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on antitumor agents, 2. Syntheses and antitumor activities of 1-(tetrahydro-2-furanyl)-5-fluorouracil and 1,3-bis(tetrahydro-2-furanyl)-5-fluorouracil.
    Yasumoto M; Yamawaki I; Marunaka T; Hashimoto S
    J Med Chem; 1978 Aug; 21(8):738-41. PubMed ID: 357721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism, antitumor activity, and acute toxicity of 5-fluoro-1,3-bis(tetrahydro-2-furanyl)-2,4-pyrimidinedione by oral administration to animals.
    Fujii S; Nakamura Y; Takeda S; Morita K; Sato T; Marunaka T; Kawaguchi Y; Unemi N
    Gan; 1980 Feb; 71(1):30-44. PubMed ID: 6769737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Studies of antitumor agents. 1. Resolution of racemic 1-(tetrahydro-2-furanyl)-k-fluorouracil into the R and S isomers and examination of the biological activities of the isomers.
    Yasumoto M; Moriyama A; Unemi N; Hashimoto S; Suzue T
    J Med Chem; 1977 Dec; 20(12):1592-4. PubMed ID: 338900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of 5-fluorouracil analogs on humoral and cell-mediated responses in mice: augmentation of delayed hypersensitivity response against picryl chloride by 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione (FD-1), a new anti-tumor drug.
    Yamada Y; Miyauchi S; Unemi N
    J Clin Lab Immunol; 1980 Nov; 4(3):153-7. PubMed ID: 6451710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects on 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione(FD-1) on the central nervous system: 1. Effects on monoamines in the brain.
    Toide K; Kitazato K; Unemi N
    Arch Int Pharmacodyn Ther; 1980 Oct; 247(2):243-56. PubMed ID: 6778400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative determination of 1,3-bis(tetrahydro-2-furanyl)-5-fluoro-2,4-pyrimidinedione and its metabolites in visceral tissues by high-performance liquid chromatography and gas chromatography-mass fragmentography.
    Marunaka T; Umeno Y; Minami Y
    J Chromatogr; 1980 Jan; 188(1):270-2. PubMed ID: 6769934
    [No Abstract]   [Full Text] [Related]  

  • 10. 5-Fluorouracil concentrations in human plasma following R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) administration.
    Au JL; Sadée W
    Cancer Res; 1979 Oct; 39(10):4289-90. PubMed ID: 383283
    [No Abstract]   [Full Text] [Related]  

  • 11. [Clinical experiences with UFD-1].
    Furue H
    Gan To Kagaku Ryoho; 1982 Apr; 9(4):672-4. PubMed ID: 6820905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disposition and metabolism of 1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) in humans.
    Benvenuto JA; Lu K; Hall SW; Benjamin RS; Loo TL
    Cancer Res; 1978 Nov; 38(11 Pt 1):3867-70. PubMed ID: 359130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of Ftorafue [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil] to 5-fluorouracil and gamma-butyrolactone.
    Au JL; Sadée W
    Cancer Res; 1980 Aug; 40(8 Pt 1):2814-9. PubMed ID: 6771006
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel prodrugs of tegafur that display improved anticancer activity and antiangiogenic properties.
    Engel D; Nudelman A; Tarasenko N; Levovich I; Makarovsky I; Sochotnikov S; Tarasenko I; Rephaeli A
    J Med Chem; 2008 Jan; 51(2):314-23. PubMed ID: 18163551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic activation of R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil (ftorafur) to 5-fluorouracil by soluble enzymes.
    El Sayed YM; Sadée W
    Cancer Res; 1983 Sep; 43(9):4039-44. PubMed ID: 6409396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enzymatic formation of 5-fluorouracil from 1-(tetrahydro-2-furanyl)- 5-fluorouracil (tegafur) in human tumor tissues.
    Kono A; Hara Y; Matsushima Y
    Chem Pharm Bull (Tokyo); 1981 May; 29(5):1486-8. PubMed ID: 6794918
    [No Abstract]   [Full Text] [Related]  

  • 17. [Synthesis of 3-(tetrahydro-2-furanyl)-5-fluorouracil (author's transl)].
    Yasumoto M; Yamashita J; Hashimoto S
    Yakugaku Zasshi; 1978 Nov; 98(11):1551-3. PubMed ID: 368311
    [No Abstract]   [Full Text] [Related]  

  • 18. Fluorescence determination of 5-fluorouracil and 1-(tetrahydro-2-furanyl)-5-fluorouracil in blood serum by high-performance liquid chromatography.
    Iwamoto M; Yoshida S; Hirose S
    J Chromatogr; 1984 Sep; 310(1):151-7. PubMed ID: 6438145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacology of ftorafur (R, S-1-(tetrahydro-2-furanyl)-5-fluorouracil.
    Au JL; Sadée W
    Recent Results Cancer Res; 1981; 76():100-14. PubMed ID: 6785848
    [No Abstract]   [Full Text] [Related]  

  • 20. Identification of metabolites of 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT-207) formed in vitro by rat liver microsomes.
    Marunaka T; Minami Y; Umeno Y; Yasuda A; Sato T; Fujii S
    Chem Pharm Bull (Tokyo); 1980 Jun; 28(6):1795-80. PubMed ID: 6773678
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.